On March 24, 2026, Ocugen, Inc. reported topline data from the Phase 2 ArMaDa clinical trial evaluating its OCU410 gene therapy for geographic atrophy caused by dry age-related macular degeneration, and a conference call is scheduled for the same day to discuss the data.